SLC24A2: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SLC24A2

NCBI ID: G25769

SLC24A2

SLC24A2: A Potential Drug Target and Biomarker for Various Diseases

SLC24A2 (SLC24A2 variant 1) is a gene that encodes a protein known as solute carrier family 24 member 2. The solute carrier family 24 member 2 protein is a transmembrane protein that is involved in the transport of various substances, including drugs, across cell membranes. SLC24A2 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and neurological disorders.

The SLC24A2 protein is expressed in most tissues and cells of the body and is involved in the transport of various substances across cell membranes, including drugs. It is a member of the solute carrier family 24, which includes proteins that are involved in the transport of a wide variety of substances, including drugs, across cell membranes. SLC24A2 is a 24kDa protein that consists of 210 amino acid residues. It has a single transmembrane domain and a N-terminus that is involved in the cytoplasmic side of the cell membrane.

SLC24A2 has been identified as a potential drug target and biomarker for various diseases due to its involvement in the transport of drugs across cell membranes. Many drugs that are used to treat various diseases, including cancer, neurodegenerative diseases, and neurological disorders, are designed to be transported across cell membranes and are therefore targeted to the SLC24A2 protein. This means that drugs that are designed to interact with SLC24A2, such as inhibitors, may be able to inhibit its function and have therapeutic effects on diseases that are characterized by the overuse or dysfunction of SLC24A2.

In addition to its potential as a drug target, SLC24A2 has also been identified as a potential biomarker for various diseases. The SLC24A2 protein is expressed in most tissues and cells of the body and is involved in the transport of various substances across cell membranes, including drugs. This means that the levels of SLC24A2 in tissues and cells can be used as a biomarker for various diseases. For example, the levels of SLC24A2 in cancer cells may be increased compared to healthy cells, making it an potential biomarker for cancer. Similarly, the levels of SLC24A2 in neurodegenerative diseases, such as Alzheimer's disease, may be increased compared to healthy cells, making it an potential biomarker for these diseases.

SLC24A2 has also been identified as a potential target for small molecules, including inhibitors, due to its involvement in the transport of drugs across cell membranes. Many small molecules that are used to treat various diseases, including cancer, neurodegenerative diseases, and neurological disorders, are designed to interact with SLC24A2 and may be targeted to its function. This means that SLC24A2 may be a useful target for small molecules that are used to treat these diseases.

In conclusion, SLC24A2 is a gene that encodes a protein involved in the transport of various substances across cell membranes, including drugs. It has been identified as a potential drug target and biomarker for various diseases due to its involvement in the transport of drugs across cell membranes. The levels of SLC24A2 in tissues and cells can be used as a biomarker for these diseases, and SLC24A2 may also be a target for small molecules that are used to treat various diseases. Further research is needed to fully understand the role of SLC24A2 as a drug target and biomarker for various diseases.

Protein Name: Solute Carrier Family 24 Member 2

Functions: Calcium, potassium:sodium antiporter that transports 1 Ca(2+) and 1 K(+) in exchange for 4 Na(+) (PubMed:10662833, PubMed:26631410). Required for learming and memory by regulating neuronal Ca(2+), which is essential for the development of synaptic plasticity (By similarity)

The "SLC24A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC24A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets